Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study This is an ASCO Meeting Abstract ...
Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Background: CML patients with different types of BCR-ABL ...
Thirteen patients were treated during study (Table 1). Vaccination was generally well tolerated with the most common toxicity being local induration or erythema at the site of inoculation. Eleven ...
Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, ...
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from ...
—Michael J. Mauro, MD, leader of the Myeloproliferative Neoplasms Program, Leukemia Service, at Memorial Sloan Kettering Cancer Center, discusses the current understanding of TKI discontinuation and ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michael J. Mauro, ...
FOSTER CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results